HC Wainwright Has Optimistic Outlook of RAPT FY2024 Earnings

RAPT Therapeutics, Inc. (NASDAQ:RAPT) – Investment analysts at HC Wainwright lifted their FY2024 earnings estimates for RAPT Therapeutics in a report released on Monday, November 25th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($2.56) for the year, up from their previous forecast of ($2.70). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for RAPT Therapeutics’ current full-year earnings is ($2.73) per share. HC Wainwright also issued estimates for RAPT Therapeutics’ Q4 2024 earnings at ($0.58) EPS, Q2 2025 earnings at ($0.66) EPS, Q3 2025 earnings at ($0.69) EPS, Q4 2025 earnings at ($0.63) EPS and FY2025 earnings at ($2.61) EPS.

Several other equities research analysts also recently issued reports on RAPT. Wells Fargo & Company reduced their price objective on RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating for the company in a research note on Tuesday, November 12th. JPMorgan Chase & Co. cut shares of RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a report on Monday, November 11th. Piper Sandler downgraded shares of RAPT Therapeutics from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $8.00 to $2.00 in a research report on Monday, November 11th. Stifel Nicolaus reiterated a “hold” rating and issued a $2.00 target price (down previously from $7.00) on shares of RAPT Therapeutics in a research report on Wednesday, November 13th. Finally, UBS Group lowered their price target on shares of RAPT Therapeutics from $10.00 to $2.00 and set a “neutral” rating on the stock in a report on Monday, September 9th. One analyst has rated the stock with a sell rating, ten have given a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $9.50.

RAPT Therapeutics Stock Up 9.8 %

Shares of RAPT Therapeutics stock opened at $1.23 on Wednesday. RAPT Therapeutics has a 12 month low of $1.00 and a 12 month high of $27.35. The stock has a market cap of $43.00 million, a PE ratio of -0.44 and a beta of 0.33. The business has a fifty day simple moving average of $1.80 and a 200-day simple moving average of $2.61.

RAPT Therapeutics (NASDAQ:RAPT) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.09.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of RAPT. Hennion & Walsh Asset Management Inc. boosted its holdings in RAPT Therapeutics by 8.6% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 48,525 shares of the company’s stock worth $148,000 after purchasing an additional 3,824 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in shares of RAPT Therapeutics in the first quarter worth about $97,000. Readystate Asset Management LP bought a new stake in shares of RAPT Therapeutics during the 3rd quarter worth about $36,000. Bank of New York Mellon Corp increased its holdings in shares of RAPT Therapeutics by 24.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 114,590 shares of the company’s stock valued at $349,000 after acquiring an additional 22,175 shares during the last quarter. Finally, Barclays PLC raised its stake in shares of RAPT Therapeutics by 277.2% in the 3rd quarter. Barclays PLC now owns 39,729 shares of the company’s stock valued at $79,000 after acquiring an additional 29,195 shares in the last quarter. Institutional investors and hedge funds own 99.09% of the company’s stock.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.